NRSN
NeuroSense Therapeutics Ltd.
Biotechnology
Market Cap$20M
5Y Perf.-64.2%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
NRSN vs SAVA vs ACIU vs AVXL
Revenue, margins, valuation, and 5-year total return — side by side.
SAVA
Cassava Sciences, Inc.
Biotechnology
Market Cap$94M
5Y Perf.-63.5%
ACIU
AC Immune S.A.
Biotechnology
Market Cap$291M
5Y Perf.-42.2%
AVXL
Anavex Life Sciences Corp.
Biotechnology
Market Cap$298M
5Y Perf.-81.4%
NRSN vs SAVA vs ACIU vs AVXL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | NRSN | SAVA | ACIU | AVXL |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $20M | $94M | $291M | $298M |
| Revenue (TTM) | $0.00 | $0.00 | $4M | $0.00 |
| Net Income (TTM) | $-9M | $-106M | $-70M | $-40M |
| Gross Margin | — | — | 100.0% | — |
| Operating Margin | — | — | -19.3% | — |
| Total Debt | $73K | $0.00 | $5M | $0.00 |
| Cash & Equiv. | $3M | $129M | $27M | $103M |
NRSN vs SAVA vs ACIU vs AVXL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NRSN
SAVA
ACIU
AVXL
| Stock | Dec 21 | May 26 | Return |
|---|---|---|---|
| NeuroSense Therapeu… (NRSN) | 100 | 35.8 | -64.2% |
| Cassava Sciences, I… (SAVA) | 100 | 36.5 | -63.5% |
| AC Immune S.A. (ACIU) | 100 | 57.8 | -42.2% |
| Anavex Life Science… (AVXL) | 100 | 18.6 | -81.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NRSN vs SAVA vs ACIU vs AVXL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NRSN leads in 2 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Cassava Sciences, Inc. is the stronger pick specifically for profitability and margin quality. ACIU and AVXL also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
NRSN
NeuroSense Therapeutics Ltd.
The Income Pick
NRSN carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.26
- Lower volatility, beta 1.26, Low D/E 2.8%, current ratio 2.21x
- Beta 1.26, current ratio 2.21x
- -2.8% revenue growth vs SAVA's -5.4%
Best for: income & stability and sleep-well-at-night
SAVA
Cassava Sciences, Inc.
The Growth Play
SAVA is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- EPS growth 77.6%
- -19.5% 10Y total return vs AVXL's -23.3%
- 5.4% margin vs ACIU's -19.7%
Best for: growth exposure and long-term compounding
ACIU
AC Immune S.A.
The Momentum Pick
ACIU is the clearest fit if your priority is momentum.
- +72.3% vs AVXL's -62.4%
Best for: momentum
AVXL
Anavex Life Sciences Corp.
The Niche Pick
AVXL is the clearest fit if your priority is efficiency.
- -30.0% ROA vs NRSN's -5.1%
Best for: efficiency
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NRSN | -2.8% revenue growth vs SAVA's -5.4% |
| Quality / Margins | SAVA | 5.4% margin vs ACIU's -19.7% |
| Stability / Safety | NRSN | Beta 1.26 vs SAVA's 1.99 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | ACIU | +72.3% vs AVXL's -62.4% |
| Efficiency (ROA) | AVXL | -30.0% ROA vs NRSN's -5.1% |
NRSN vs SAVA vs ACIU vs AVXL — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSAVALAGGINGNRSN
Who Leads Where
SAVA leads in 1 of 6 categories
AVXL leads 1 • ACIU leads 1 • NRSN leads 0 • 2 tied
Explore the data ↓NRSNNeuroSense Therapeuti…
0leads
AVXLAnavex Life Sciences …
1leads
ACIUAC Immune S.A.
1leads
SAVACassava Sciences, Inc.
1leads
6 Total Categories
CATEGORYLEADERvs ACIUvs AVXLMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SAVA1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
AVXL4/9
Total Returns1Y, 3Y, 5Y total returns with dividends
ACIU4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SAVA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ACIU and AVXL operate at a comparable scale, with $4M and $0 in trailing revenue.
| Metric | NRSNNeuroSense Therap… | SAVACassava Sciences,… | ACIUAC Immune S.A. | AVXLAnavex Life Scien… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $0 | $4M | $0 |
| EBITDAEarnings before interest/tax | -$9M | -$110M | -$67M | -$30M |
| Net IncomeAfter-tax profit | -$9M | -$106M | -$70M | -$40M |
| Free Cash FlowCash after capex | -$2,000 | -$84M | -$70M | -$34M |
| Gross MarginGross profit ÷ Revenue | — | — | +100.0% | — |
| Operating MarginEBIT ÷ Revenue | — | — | -19.3% | — |
| Net MarginNet income ÷ Revenue | — | — | -19.7% | — |
| FCF MarginFCF ÷ Revenue | — | — | -19.6% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | -70.3% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -95.2% | +62.1% | +6.7% | +54.4% |
SAVA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — SAVA and AVXL each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | NRSNNeuroSense Therap… | SAVACassava Sciences,… | ACIUAC Immune S.A. | AVXLAnavex Life Scien… |
|---|---|---|---|---|
| Market CapShares × price | $20M | $94M | $291M | $298M |
| Enterprise ValueMkt cap + debt − cash | $17M | -$34M | $263M | $196M |
| Trailing P/EPrice ÷ TTM EPS | -1.60x | -3.76x | -3.19x | -5.96x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — | 63.53x | — |
| Price / BookPrice ÷ Book value/share | 6.34x | 0.63x | 5.00x | 2.89x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
Evenly matched — SAVA and AVXL each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
AVXL leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
AVXL delivers a -31.5% return on equity — every $100 of shareholder capital generates $-32 in annual profit, vs $-29 for NRSN. NRSN carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to ACIU's 0.10x. On the Piotroski fundamental quality scale (0–9), NRSN scores 3/9 vs AVXL's 2/9, reflecting mixed financial health.
| Metric | NRSNNeuroSense Therap… | SAVACassava Sciences,… | ACIUAC Immune S.A. | AVXLAnavex Life Scien… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -28.8% | -95.8% | -101.6% | -31.5% |
| ROA (TTM)Return on assets | -5.1% | -75.3% | -38.7% | -30.0% |
| ROICReturn on invested capital | — | -6.3% | -99.2% | — |
| ROCEReturn on capital employed | -8.6% | -99.9% | -72.6% | -47.8% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 | 2 | 2 |
| Debt / EquityFinancial leverage | 0.03x | — | 0.10x | — |
| Net DebtTotal debt minus cash | -$3M | -$129M | -$22M | -$103M |
| Cash & Equiv.Liquid assets | $3M | $129M | $27M | $103M |
| Total DebtShort + long-term debt | $73,000 | $0 | $5M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -97.39x | — | -482.85x | — |
AVXL leads this category, winning 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
ACIU leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACIU five years ago would be worth $4,689 today (with dividends reinvested), compared to $2,178 for NRSN. Over the past 12 months, ACIU leads with a +72.3% total return vs AVXL's -62.4%. The 3-year compound annual growth rate (CAGR) favors ACIU at 10.7% vs AVXL's -27.4% — a key indicator of consistent wealth creation.
| Metric | NRSNNeuroSense Therap… | SAVACassava Sciences,… | ACIUAC Immune S.A. | AVXLAnavex Life Scien… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +12.8% | -6.5% | -14.9% | -12.5% |
| 1-Year ReturnPast 12 months | -16.2% | +15.0% | +72.3% | -62.4% |
| 3-Year ReturnCumulative with dividends | -49.1% | -40.8% | +35.5% | -61.7% |
| 5-Year ReturnCumulative with dividends | -78.2% | -64.6% | -53.1% | -70.4% |
| 10-Year ReturnCumulative with dividends | -78.2% | -19.5% | -81.7% | -23.3% |
| CAGR (3Y)Annualised 3-year return | -20.2% | -16.0% | +10.7% | -27.4% |
ACIU leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — NRSN and ACIU each lead in 1 of 2 comparable metrics.
Risk & Volatility
NRSN is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than SAVA's 1.99 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACIU currently trades 71.5% from its 52-week high vs AVXL's 23.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NRSNNeuroSense Therap… | SAVACassava Sciences,… | ACIUAC Immune S.A. | AVXLAnavex Life Scien… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.26x | 1.99x | 1.54x | 1.45x |
| 52-Week HighHighest price in past year | $2.60 | $4.98 | $4.00 | $13.99 |
| 52-Week LowLowest price in past year | $0.63 | $1.54 | $1.51 | $2.61 |
| % of 52W HighCurrent price vs 52-week peak | +33.8% | +39.3% | +71.5% | +23.0% |
| RSI (14)Momentum oscillator 0–100 | 59.9 | 46.8 | 47.5 | 40.4 |
| Avg Volume (50D)Average daily shares traded | 156K | 727K | 266K | 1.4M |
Evenly matched — NRSN and ACIU each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: SAVA as "Buy", ACIU as "Buy", AVXL as "Buy". Consensus price targets imply 241.6% upside for AVXL (target: $11) vs 144.8% for ACIU (target: $7).
| Metric | NRSNNeuroSense Therap… | SAVACassava Sciences,… | ACIUAC Immune S.A. | AVXLAnavex Life Scien… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | — | $7.00 | $11.00 |
| # AnalystsCovering analysts | — | 12 | 9 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 1 | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SAVA leads in 1 of 6 categories (Income & Cash Flow). AVXL leads in 1 (Profitability & Efficiency). 2 tied.
Best OverallCassava Sciences, Inc. (SAVA)Leads 1 of 6 categories
Loading custom metrics...
NRSN vs SAVA vs ACIU vs AVXL: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is NRSN or SAVA or ACIU or AVXL a better buy right now?
Analysts rate Cassava Sciences, Inc.
(SAVA) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — NRSN or SAVA or ACIU or AVXL?
Over the past 5 years, AC Immune S.
A. (ACIU) delivered a total return of -53. 1%, compared to -78. 2% for NeuroSense Therapeutics Ltd. (NRSN). Over 10 years, the gap is even starker: SAVA returned -19. 5% versus ACIU's -81. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — NRSN or SAVA or ACIU or AVXL?
By beta (market sensitivity over 5 years), NeuroSense Therapeutics Ltd.
(NRSN) is the lower-risk stock at 1. 26β versus Cassava Sciences, Inc. 's 1. 99β — meaning SAVA is approximately 58% more volatile than NRSN relative to the S&P 500. On balance sheet safety, NeuroSense Therapeutics Ltd. (NRSN) carries a lower debt/equity ratio of 3% versus 10% for AC Immune S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — NRSN or SAVA or ACIU or AVXL?
On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc.
grew EPS 77. 6% year-over-year, compared to -37. 3% for AC Immune S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — NRSN or SAVA or ACIU or AVXL?
NeuroSense Therapeutics Ltd.
(NRSN) is the more profitable company, earning 0. 0% net margin versus -1971. 6% for AC Immune S. A. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NRSN leads at 0. 0% versus -1927. 3% for ACIU. At the gross margin level — before operating expenses — ACIU leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — NRSN or SAVA or ACIU or AVXL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is NRSN or SAVA or ACIU or AVXL better for a retirement portfolio?
For long-horizon retirement investors, NeuroSense Therapeutics Ltd.
(NRSN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Cassava Sciences, Inc. (SAVA) carries a higher beta of 1. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NRSN: -78. 2%, SAVA: -19. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between NRSN and SAVA and ACIU and AVXL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.